Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
57.2M
-
Number of holders
-
58
-
Total 13F shares, excl. options
-
36.2M
-
Shares change
-
+2.27M
-
Total reported value, excl. options
-
$773M
-
Value change
-
+$50.2M
-
Number of buys
-
41
-
Number of sells
-
-7
-
Price
-
$21.41
Significant Holders of Design Therapeutics, Inc. - Common Stock (DSGN) as of Q4 2021
62 filings reported holding DSGN - Design Therapeutics, Inc. - Common Stock as of Q4 2021.
Design Therapeutics, Inc. - Common Stock (DSGN) has 58 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36.2M shares
of 57.2M outstanding shares and own 63.28% of the company stock.
Largest 10 shareholders include SR ONE CAPITAL MANAGEMENT, LP (5.63M shares), Cormorant Asset Management, LP (5.44M shares), Logos Global Management LP (2.77M shares), CITADEL ADVISORS LLC (2.53M shares), BlackRock Inc. (2.22M shares), RA CAPITAL MANAGEMENT, L.P. (2.19M shares), EcoR1 Capital, LLC (2.15M shares), VANGUARD GROUP INC (1.87M shares), Avoro Capital Advisors LLC (1.64M shares), and BAKER BROS. ADVISORS LP (1.44M shares).
This table shows the top 58 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.